Genistein in Treating Patients With Prostate Cancer
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
In brief
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.
Key facts
- Study ID
- NCT01126879
- Run by
- Northwestern University
- People needed
- 12
- Starts
- 2011-02-03
- Expected to finish
- 2013-12-28
- Last updated by the study team
- 2019-09-10
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.